home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences  

483 Covers a Broad Gradation of Problems

  August 09, 2017  
Netzealous LLC DBA - Compliance4All, Online

How you respond to the 483 should provide the foundation for any future 

communication with the FDA about a particular inspection. Understanding how 

FDA organizes its evaluation of the 483 can facilitate the FDA’s review in your 

favor as it is well organized, succinct and provides proper documentation. 

Why You Should Attend:
Your failure to understand and properly respond to a 483 issued to you at the 

conclusion of an FDA inspection may quickly lead to an administrative or a 

legal action that can have an immediate adverse effect on a firm’s business.

Areas Covered in the Session:
What the 483 means
How to interpret the 483 - "How bad is it?"
Managing the 483 discussion with the FDA at the conclusion of the inspection
Responding to the FDA in writing 

Who Will Benefit:
FDA Consultants
Legal Counsel
Regulatory Affairs Managers
Quality Assurance Staff

Contact Detail:
Compliance4All DBA NetZealous,
Phone: +1-800-447-9407
Email: support@compliance4All.com
Organized by: Event Manager
Invited Speakers:
Speaker Profile:
Casper (Cap) Uldriks, through his firm “Encore Insight LLC,” brings over 32 

years of experience from the FDA. He specialized in the FDA’s medical device 

program as a field investigator, served as a senior manager in the Office of 

Compliance and an Associate Center Director for the Center for Devices and 

Radiological Health.
Deadline for Abstracts: 2017-10-24
Full Details & Registration Link:
E-mail: support@compliance4All.com
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.